Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Huang, Guangzhou
Bendong Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100021568 | Anti-Obesity Product And Its Method Of Preparation - The present invention relates to compositions comprising one or more anthraquinones for use in the treatment of obesity and related metabolic and liver disease. More particularly it relates to a plant extract fraction rich in anthraquinones including both anthraquinone glycosides and anthraquinone aglycones obtainable from a member of the Leguminosae family, more particularly | 01-28-2010 |
Bijun Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20080267992 | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine - The present invention relates to the field of biological engineering technology, specifically, to a SARS virus vaccine with adenovirus carrier, preparation method thereof and use of SARS virus S gene for preparation of severe acute respiratory syndrome (SARS) virus vaccine. | 10-30-2008 |
Cai Gu Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20090215787 | Preparations of new polymorphic forms of varenicline tartrate - The present invention is directed to an amorphous form, three novel polymorph form of crystalline varenicline tartrate, namely Form D, Form E and Form F. The present invention also provides processes of their preparations and pharmaceutical composition comprising such material and their use in therapy. Form D is new anhydrous varenicline tartrate, and can be prepared from recrystallizing varenicline tartrate in a mixture of methanol and water or a mixture of N,N-dimethylformamide and water. Form E is a new varenicline tartrate monohydrate, and can be prepared recrystallizing varenicline tartrate in a mixture of isopropanol and water. Form F is another new varenicline tartrate monohydrate, and can be prepared recrystallizing varenicline tartrate in a mixture of acetone and water. The X-ray powder diffraction pattern (X-RPD), Fourier transform infrared (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) techniques are used to characterize amorphous form and crystalline polymorphic forms. | 08-27-2009 |
| 20090247532 | Crystalline polymorph of sitagliptin phosphate and its preparation - The present invention is directed to a novel polymorph form of crystalline sitagliptin phosphate, named as Form V herein. The present invention further provides processes for preparations of Form V, pharmaceutical composition comprising Form V and its use in therapy. Form V can be prepared from recrystallizing sitagliptin phosphate in a mixture of methanol and water, a mixture of acetone and water, or from distillation of a mixture of organic solvents and water followed by recrystallization in the remaining aqueous solution. | 10-01-2009 |
Ding Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20110162091 | METHOD OF DEACTIVATION AFTER SOFTWARE BEING ACTIVATED ONLINE - A method of deactivation after software being activated online is provided, including: online-activated software sending a deactivation request message and its license key to a network server; the request being validated by the server inquiring its file system; if the request being valid, the server changing the status of the license key into “deactivated” or deleting the license key and its associate information in its file system and sending a deactivation permission message to the software; after receiving the deactivation permission message the software deleting or modifying local activation information promptly to ensure the software cannot run in activated status any more. By this method, an activated software user could initiatively deactivate the software on its current hardware device and then activate the software on another hardware device. The method of the invention enables user to transfer the software license to another hardware device initiatively. | 06-30-2011 |
Fei Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100051915 | POLYMER CHARGE TRANSPORT MATERIAL FOR OPTOELECTRONIC DEVICES - Polymers that enable the use of high work-function metals as a cathode in optoelectronic devices and optoelectronic devices incorporating the polymers as an electron transport layer. | 03-04-2010 |
Hui Min He Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20090215787 | Preparations of new polymorphic forms of varenicline tartrate - The present invention is directed to an amorphous form, three novel polymorph form of crystalline varenicline tartrate, namely Form D, Form E and Form F. The present invention also provides processes of their preparations and pharmaceutical composition comprising such material and their use in therapy. Form D is new anhydrous varenicline tartrate, and can be prepared from recrystallizing varenicline tartrate in a mixture of methanol and water or a mixture of N,N-dimethylformamide and water. Form E is a new varenicline tartrate monohydrate, and can be prepared recrystallizing varenicline tartrate in a mixture of isopropanol and water. Form F is another new varenicline tartrate monohydrate, and can be prepared recrystallizing varenicline tartrate in a mixture of acetone and water. The X-ray powder diffraction pattern (X-RPD), Fourier transform infrared (FT-IR), differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) techniques are used to characterize amorphous form and crystalline polymorphic forms. | 08-27-2009 |
| 20090247532 | Crystalline polymorph of sitagliptin phosphate and its preparation - The present invention is directed to a novel polymorph form of crystalline sitagliptin phosphate, named as Form V herein. The present invention further provides processes for preparations of Form V, pharmaceutical composition comprising Form V and its use in therapy. Form V can be prepared from recrystallizing sitagliptin phosphate in a mixture of methanol and water, a mixture of acetone and water, or from distillation of a mixture of organic solvents and water followed by recrystallization in the remaining aqueous solution. | 10-01-2009 |
Jialing Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20080267992 | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine - The present invention relates to the field of biological engineering technology, specifically, to a SARS virus vaccine with adenovirus carrier, preparation method thereof and use of SARS virus S gene for preparation of severe acute respiratory syndrome (SARS) virus vaccine. | 10-30-2008 |
Michael Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20090011054 | Plant-based formulations for improving liver health - The present invention is directed to plant based formulations for improving liver health by protecting the liver from alcohol and chemical insults and/or by inducing phase II enzymes. Formulations according to the present invention include wasabi root fiber powder, artichoke leaf extract, asparagus dehydrate, kudzu root extract, oregano extract, schisandra berry extract, notoginseng (ethanol extract of | 01-08-2009 |
Tianzai Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20090273272 | MULTI-ELECTRODE FLUORESCENT LAMP TUBE - A fluorescent lamp with a multiple electrodes at each input, where 3 to 8 electrodes may be installed in a single electrode holder sealed at each end of the fluorescent lamp tube. In operation, electron discharge primarily only occurs from one electrode at each input end, which has smallest resistance. With multiple electrodes, the electron discharge function at each input end will last one to several times longer, compared with the input end with just a single electrode. Because the life span of the fluorescent lamp depends on the electron discharge function at each input end, multiple electrodes at each input end increases the overall service life of the lamp. This invention increases cost-effectiveness of the fluorescent lamp without requiring complex structural modifications. | 11-05-2009 |
Wenlin Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20080267992 | Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine - The present invention relates to the field of biological engineering technology, specifically, to a SARS virus vaccine with adenovirus carrier, preparation method thereof and use of SARS virus S gene for preparation of severe acute respiratory syndrome (SARS) virus vaccine. | 10-30-2008 |
Wen Xiong Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100104518 | CHEWING GUM, CONFECTION, AND OTHER ORAL DELIVERY VEHICLES CONTAINING A TRADITIONAL CHINESE MEDICINE OR EXTRACT THEREOF - A method for producing a chewing gum with a controlled release traditional Chinese medicine active agent, as well as the chewing gum so produced, is obtained by physically modifying the release properties of the traditional Chinese medicine active agent by coating and drying. The traditional Chinese medicine active agent is coated by encapsulation, partially coated by agglomeration, entrapped by absorption, or treated by multiple steps of encapsulation, agglomeration, and absorption. The coated traditional Chinese medicine active agent is preferably then co-dried and particle sized to produce a release-modified traditional Chinese medicine active agent for use in chewing gum. The traditional Chinese medicine active agent may also be used in a coating on a chewing gum product, as part of a rolling compound applied to the chewing gum product, or as a part of the liquid in a liquid-center chewing gum product. | 04-29-2010 |
Xianbo Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100267923 | SEMI-AROMATIC POLYAMIDE AND A METHOD FOR PREPARATION WITH LOW WASTEWATER DISCHARGE - The present invention relates to a semi-aromatic polyamide and a method for preparing it with low wastewater discharge. The semi-aromatic polyamide for the present invention is obtained by introducing aromatic dicarboxylic acid, aliphatic diamine containing 4˜14 carbon atoms and the wastewater generated during the previous prepolymerization into an autoclave for prepolymerization reaction and then further polymerizing the prepolymer. In this preparation method, the wastewater generated during polymerization is recycled, thus greatly reducing the wastewater discharge; the raw materials in the wastewater are effectively recycled, thus improving the utilization rate of raw materials; meanwhile, the diamine in the wastewater compensates that lost along with water discharge during prepolymerization, thus ensuring the Mole ratio balance between dicarboxylic acid monomer and diamine monomer. | 10-21-2010 |
Xiaoling Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100261787 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to application of 4,4′-diphenylmethane-bis(methyl)carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-14-2010 |
| 20100267819 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover, the pharmaceutical composition is mainly used for the prevention and cure of diabetic nephropathy. For the abundant material, remarkable effect on prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-21-2010 |
| 20110053872 | Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy. | 03-03-2011 |
Yanxia Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100261787 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to application of 4,4′-diphenylmethane-bis(methyl)carbamates (DPMC) extracted and isolated from Cortex Mori and preparation of medicine for diabetic nephropathy. The pharmaceutical composition is made up of DPMC as active ingredient and the normal drug carriers, and the weight percentage of active ingredient is 0.1-99.5%. For the remarkable effect of prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-14-2010 |
| 20100267819 | PHARMACEUTICAL COMPOSITION FOR DIABETIC NEPHROPATHY AND ITS PREPARATION AND APPLICATION - The invention relates to a pharmaceutical composition for diabetic nephropathy and its preparation, and the application in preparing of medicine for diabetic nephropathy. The pharmaceutical composition is made up of at least one of 7-hydroxycoumarin and 7-hydroxy-6-methoxycoumarin as active ingredient, and the weight percentage of active ingredient is 0.1-99.5%. Moreover, the pharmaceutical composition is mainly used for the prevention and cure of diabetic nephropathy. For the abundant material, remarkable effect on prevention and cure for diabetic nephropathy and convenience for use, it will be a new facultative drug for patients. | 10-21-2010 |
| 20110053872 | Pharmaceutical Composition For Preventing And Treating Diabetic Nephropathy And The Preparation Method Thereof - The present invention relates to a pharmaceutical composition for preventing and treating diabetic complications, mainly referring to diabetic nephropathy, and the pharmaceutical composition comprises one or both of calycosin and calycosin-7-O-β-D-glucoside as 0.1˜99.5% by weight based on the total weight of the composition, and the conventional drug carrier. The pharmaceutical composition could significantly prevent and treat diabetic nephropathy, with the convenience of quality control and administration, which provides a new drug candidate for patients with diabetic nephropathy. | 03-03-2011 |
Yaoxiong Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20110159591 | Genetic material and chromosomal processing and manipulation methods - The presently claimed invention applies to a genetic material processing and manipulation method and related product. The claimed invention relates to a method for changing the inherited characteristics of a cell through chromosome processing treatment. In a preferred embodiment, ‘genomic surgery’ is applied to source genetic material | 06-30-2011 |
Yijun Huang, Guangzhou CN
| Patent application number | Description | Published |
|---|---|---|
| 20100152150 | THE APPLICATION OF MARINE STEROID IN PREPARING THE MEDICINE OF TREATING NEURONS DAMAGING - The application of marine steroid, i.e. 24-methylene-cholest-3β,5α,6β,19-tetrol, in preparing the medicine of treating neurons damaging is provided in the present invention. The keto-sterols compounds marine steroid YC-1 extracted from | 06-17-2010 |